These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 37530824)

  • 41. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
    Macfadden W; Alphs L; Haskins JT; Turner N; Turkoz I; Bossie C; Kujawa M; Mahmoud R
    Bipolar Disord; 2009 Dec; 11(8):827-39. PubMed ID: 19922552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).
    Vieta E; Suppes T; Eggens I; Persson I; Paulsson B; Brecher M
    J Affect Disord; 2008 Aug; 109(3):251-63. PubMed ID: 18579216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial.
    Bockting CLH; Klein NS; Elgersma HJ; van Rijsbergen GD; Slofstra C; Ormel J; Buskens E; Dekker J; de Jong PJ; Nolen WA; Schene AH; Hollon SD; Burger H
    Lancet Psychiatry; 2018 May; 5(5):401-410. PubMed ID: 29625762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does recent mania affect response to antidepressants in bipolar disorder? A re-analysis of STEP-BD data.
    Mousavi Z; Johnson S; Li D
    J Affect Disord; 2018 Aug; 236():136-139. PubMed ID: 29734096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
    van der Loos ML; Mulder PG; Hartong EG; Blom MB; Vergouwen AC; de Keyzer HJ; Notten PJ; Luteijn ML; Timmermans MA; Vieta E; Nolen WA;
    J Clin Psychiatry; 2009 Feb; 70(2):223-31. PubMed ID: 19200421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.
    Lenze EJ; Mulsant BH; Roose SP; Lavretsky H; Reynolds CF; Blumberger DM; Brown PJ; Cristancho P; Flint AJ; Gebara MA; Gettinger TR; Lenard E; Miller JP; Nicol GE; Oughli HA; Pham VT; Rollman BL; Yang L; Karp JF
    N Engl J Med; 2023 Mar; 388(12):1067-1079. PubMed ID: 36867173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review.
    Altshuler L; Kiriakos L; Calcagno J; Goodman R; Gitlin M; Frye M; Mintz J
    J Clin Psychiatry; 2001 Aug; 62(8):612-6. PubMed ID: 11561933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data.
    Tada M; Uchida H; Mizushima J; Suzuki T; Mimura M; Nio S
    J Psychiatr Res; 2015 Sep; 68():151-6. PubMed ID: 26228414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind trial of bupropion versus desipramine for bipolar depression.
    Sachs GS; Lafer B; Stoll AL; Banov M; Thibault AB; Tohen M; Rosenbaum JF
    J Clin Psychiatry; 1994 Sep; 55(9):391-3. PubMed ID: 7929019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial.
    Sit DK; McGowan J; Wiltrout C; Diler RS; Dills JJ; Luther J; Yang A; Ciolino JD; Seltman H; Wisniewski SR; Terman M; Wisner KL
    Am J Psychiatry; 2018 Feb; 175(2):131-139. PubMed ID: 28969438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship of free thyroxine and triiodothyronine on recurrence in maintenance therapy for bipolar depression.
    Wang X; Luo J; Yuan XF; Chen X; Yu HY; Zhu XQ; Wang G
    Asian J Psychiatr; 2022 May; 71():103086. PubMed ID: 35316669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
    McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
    JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
    Tohen M; Greil W; Calabrese JR; Sachs GS; Yatham LN; Oerlinghausen BM; Koukopoulos A; Cassano GB; Grunze H; Licht RW; Dell'Osso L; Evans AR; Risser R; Baker RW; Crane H; Dossenbach MR; Bowden CL
    Am J Psychiatry; 2005 Jul; 162(7):1281-90. PubMed ID: 15994710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
    Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
    J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.
    Bowden CL; Calabrese JR; McElroy SL; Gyulai L; Wassef A; Petty F; Pope HG; Chou JC; Keck PE; Rhodes LJ; Swann AC; Hirschfeld RM; Wozniak PJ
    Arch Gen Psychiatry; 2000 May; 57(5):481-9. PubMed ID: 10807488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.
    Zeinoddini A; Sorayani M; Hassanzadeh E; Arbabi M; Farokhnia M; Salimi S; Ghaleiha A; Akhondzadeh S
    Depress Anxiety; 2015 Mar; 32(3):167-73. PubMed ID: 25620378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.